Roche and Blue­print agree to end col­lab­o­ra­tion for can­cer drug Gavre­to

Roche is re­turn­ing de­vel­op­ment and com­mer­cial­iza­tion rights for can­cer drug Gavre­to to Blue­print Med­i­cines.

The two com­pa­nies are dis­solv­ing their col­lab­o­ra­tion fol­low­ing a Roche de­ci­sion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER